Aurinia Pharmaceuticals (AUPH)

• Market cap: $2.09B
• 1 day: -0.19%
• 5 days: -0.94%
• 1 month: 1.99%
• 3 months: 24.41%
• 6 months: 92.59%
• Year to date: 80.73%
• 1 year: 63.57%
• 5 years: 5.53%
• 10 years: 647.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300